SAFETY, PHARMACOKINETICS AND EFFICACY OF ONCE-A-DAY NETILMICIN AND AMIKACIN VERSUS THEIR CONVENTIONAL SCHEDULES IN PATIENTS SUFFERING FROM PELVIC INFLAMMATORY DISEASE

被引：25

作者：

IBRAHIM, S ^{[1
]}

DERDE, MP ^{[1
]}

KAUFMAN, L ^{[1
]}

CLERCKXBRAUN, F ^{[1
]}

JACQMIN, P ^{[1
]}

BRULEIN, V ^{[1
]}

DONNEZ, J ^{[1
]}

TULKENS, PM ^{[1
]}

机构：

[1] CATHOLIC UNIV LOUVAIN,PHYSIOL CHEM LAB,AV HIPPOCRATE 75,BTE 7539,B-1200 BRUSSELS,BELGIUM

来源：

RENAL FAILURE | 1990年 / 12卷 / 03期

关键词：

D O I：

10.3109/08860229009065564

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The safety, pharmacokinetics and efficacy of one daily injection (qd) of amikacin (AK) and netilmicin (NT) was compared with the recommended schedules (cs), i.e. twice-daily or thrice-daily, respectively. Women (17-43 years, n = 78) suffering from pelvic inflammatory disease were randomly assigned to qd or cs of either AK (14 mg/kg per day) or NT (6.6 mg/kg per day). Biometric parameters were similar in the 4 groups and all patients recieved ampicillin (4 g/day) and tinidazole (0.8 g/day). The Repeated Measures Analysis of Variance was used to distinguish the effects of the schedules and of the drugs choice on critical parameters. Efficacy was similar in the 4 groups and not influenced by the schedule of administration. No significant differences in nephro-and oto-toxicity were observed as assessed by serum creatinine and losses of hearing at low frequencies, but early phospholipiduria and auditory losses at high frequencies were significantly reduced with the qd administration compared to cs and by AK compared to NT. These data suggest that the qd schedule of AK and of NT is as efficacious as their cs schedules, and causes less renal and auditory alterations. © 1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

页码：199 / 203

页数：5

共 18 条

[1]

Price K.E., Aminoglycoside research 1975–1985: prospects for development of improved agents, Antimicrob Agents Chemother, 29, pp. 543-548, (1986)

[2]

Lietman P.S., Aminoglycosides and spectinomycin: aminocyclitols, Principles and practice of infectious diseases, pp. 192-206, (1985)

[3]

Frame P.T., Phair J.P., Watanakunakom C., Bannister T.W.P., Pharmacologic factors associated with gentamicin nephrotoxicity in rabbits, J Infect Dis, 135, pp. 952-956, (1977)

[4]

Bennett W.M., Plamp C.E., Gilbert D.N., Parker R.A., Porter G.A., The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure, J Infect Dis, 140, pp. 576-580, (1979)

[5]

Wood C.A., Norton D.R., Kohlhepp S.J., Kohnen P.W., Porter G.A., Houghton D.C., Brummett R.E., Bennett W.M., Gilbert D.N., The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess, J Infect Dis, 158, pp. 13-22, (1988)

[6]

Pechere J.C., Bernard P.A., Gentamicin ototoxicity can be avoided if a new therapeutic regimen is used. An experimental model, (1984)

[7]

Tran Ba Huy P., Aminoglycoside ototoxicity: influence of dosage regimen on drug uptake, correlation between membrane binding and clinical features, J Drug Dev, 1, pp. 93-95, (1988)

[8]

Craig W.A., Leggett J., Totsuka K., Vogelman B., Key pharmacokinetic parameters of antibiotic efficacy in experimental animal infections, JDrug Dev, 1, pp. 7-15, (1988)

[9]

Tulkens P.M., Experimental studies on nephrotoxicity of aminoglyco-sides at low doses: mechanisms and perspectives, Am J Med, 80, 6B, pp. 105-114, (1986)

[10]

Tulkens P.M., Nephrotoxicity of aminoglycosides, Toxicol Lett, 46, pp. 107-123, (1989)

← 1 2 →